Physician profile
Lisa E Colwick
NPI 1437248705
$994.70
in general payments reported to CMS, 2019-2025
15 companies · $34.37 in 2025
The $34.37 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $260 · 2023: $311 · 2024: $235 · 2025: $34.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $297.65 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $224.70 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $189.76 | 2021-2024 | |
| Amarin Pharma, INC. | $55.48 | 2021-2022 | |
| Glaxosmithkline, LLC. | $36.12 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $30.29 | 2022 | |
| Phathom Pharmaceuticals, INC. | $24.62 | 2024 | Voquezna |
| Pfizer INC. | $23.94 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2025 | Xifaxan |
| Exact Sciences Corporation | $14.33 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $14.30 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $14.15 | 2022 | |
| Daiichi Sankyo INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Colwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.